drugset / Trial / NCT06653348
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
RandomizedParallel-groupSingle-blindPrevention
Summary
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-07-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ticagrelor | Small molecule | 60 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |
| Background | Aspirin | Small molecule | 80 mg | — |